Bristol Myers Squibb Company is hopeful that its oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib could offer a new potential mechanism of action to treat systemic lupus erythematosus (SLE), a challenging condition for drug development. The company announced on 1 June that a Phase II trial testing deucravacitinib in SLE met the primary endpoint and that it will advance the drug into Phase III testing in lupus by the end of the year.
The data are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress, and chief medical officer Samit Hirawat talked to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?